-

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2022

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2022 of $1.13 per share on the company’s common stock. The dividend is payable on September 6, 2022 to shareholders of record at the close of business on August 23, 2022. The ex-dividend date is August 22, 2022.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Contacts

Press:
Jake Sargent
jsargen3@ITS.JNJ.com

Investors:
Jessica Moore
jmoore29@its.jnj.com

Sarah Wood
swood15@its.jnj.com

Johnson & Johnson


Release Versions

Contacts

Press:
Jake Sargent
jsargen3@ITS.JNJ.com

Investors:
Jessica Moore
jmoore29@its.jnj.com

Sarah Wood
swood15@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare...

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to r...

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available appr...
Back to Newsroom